Gemelli Biotech
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Gemelli Biotech - overview
Established
2018
Location
Raleigh, NC, US
Primary Industry
Medical Devices & Equipment
About
Based in North Carolina, US, and founded in 2018 by Matt Mitcho (CEO), Gemelli Biotech Corp. is a provider of equipment that detects gastrointestinal diseases in patients. In June 2022, Gemelli Biotech Corp. raised USD 19 million in series A funding led by new investor Blue Ox Healthcare Partners, with participation from other new investors Carolina Angel Network, Cedars-Sinai Health System, and CerraCap Ventures.
The company holds partnerships with Biomedica, Unilabs, Cedars-Sinai, Sibotest, and many more. The company offers diagnostic equipment namely trio-smart and ibs-smart. Trio-smart is a three-gas breath test equipment, that analyzes the level of hydrogen, methane, and hydrogen sulfide in the patient’s breath and gives a clear picture of gut health, and detects whether it is gas, bloating, constipation, diarrhea, or anything else. Ibs-smart is an ELISA blood test that measures the level of two antibodies i.
e. anti-CdtB and anti-vinculin that causes irritable bowel syndrome (IBS). The company will use the June 2022 funding to commercialize its products and expand its sales and marketing team across the US.
Current Investors
Blue Ox Healthcare Partners, CerraCap Ventures, Carolina Angel Network
Primary Industry
Medical Devices & Equipment
Sub Industries
Biotechnology, Diagnostic Equipment, Internet
Website
http://www.gemellibiotech.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.